Endocrine therapy plays a central role in the treatment of hormone-receptor (HR)–positive metastatic breast cancer. 1 Selective aromatase inhibitors, such as anastrozole, letrozole, and ...

June 12, 2006 (Atlanta) — Women with breast cancer who are treated with the aromatase inhibitor anastrozole (Arimidex, AstraZeneca) for 5 years can lose 6% to 7% in bone-mineral density (BMD ...

SAN ANTONIO — Anastrozole reduced breast cancer risk by 49% compared with placebo for postmenopausal women at high risk for the disease, according to long-term results of the randomized ...

The drug, anastrozole, has been available for years as a breast cancer treatment, and had already been recommended for prevention by the UK's health cost regulator. But it has become the first ...

Anastrozole, a drug that blocks estrogen production in postmenopausal women, has been shown to be effective in reducing a woman s risk of developing breast cancer, especially if she is at an elevated ...

Anastrozole, a daily pill to prevent breast cancer, will now be available to thousands of more women in the UK after being cleared for wider use.. The drug has been used to treat hormone-driven ...

RESULTS: Anastrozole was as effective as tamoxifen in terms of OR (21% v 17% of patients, respectively), with clinical benefit (CR + PR + stabilization ≥ 24 weeks) observed in 59% of patients on ...

Anastrozole treatment significantly decreased the mean bone age Z-score from 4.2 to 1.3 over 6 years (P < .001). The mean predicted adult height Z-score increased from −2.1 at the start of ...

To the Editor: Mehta et al. (Aug. 2 issue) 1 report that the combination of anastrozole and fulvestrant was superior to anastrozole alone when administered as first-line endocrine therapy to North ...